Top entities: Khalil Ramadi, Sawsan Abdel-Razig, Mohamed Elsherif, Cleveland Clinic.

What category does this event fall under?

Tech — classified as medical breakthrough.

What is the sentiment of coverage?

Aggregate sentiment score: 70 on a -100 to +100 scale (negative = critical coverage, positive = favorable coverage).

Is this event still developing?

This event is archived — the story has concluded and this page is a final snapshot.

Tech medical breakthrough

NYU Abu Dhabi, Cleveland Clinic Develop Injectable Device

Q: When did this event occur?

First reported Jun 12, 2026; last updated Jun 14, 2026.

Q: What is the market impact?

General. The development of this injectable medical device by New York University and Cleveland Clinic could significantly impact the healthcare and medical device industries by offering a less invasive and more accessible treatment option for neurological conditions.

Analysis based on 7 articles · First reported Jun 12, 2026 · Last updated Jun 14, 2026

Sentiment

Attention

Articles

Market Impact

General

Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard

Market Impact

The development of this injectable medical device by New York University and Cleveland Clinic could significantly impact the healthcare and medical device industries by offering a less invasive and more accessible treatment option for neurological conditions. This innovation has the potential to create new market opportunities for medical device manufacturers and reduce healthcare costs associated with surgical procedures.

Healthcare Medical Devices Biotechnology

Event Summary

Researchers from New York University, in collaboration with Cleveland Clinic, have developed a tiny, injectable medical device designed to treat chronic pain and movement disorders. This device, about the size of a small seed, can be injected near a target nerve and delivers controlled electrical signals, powered wirelessly from outside the body. The research, published in Science Advances, aims to provide a simpler, safer, and more accessible alternative to traditional surgical implants, reducing risks and recovery times for patients. Key figures in this development include Professor Khalil Ramadi, Dr. Sawsan Abdel-Razig, and Dr. Mohamed Elsherif.

Entities Involved

per

Khalil Ramadi

Khalil Ramadi is the senior author of the study and an Assistant Professor of Bioengineering at New York University, leading the research that developed the injectable device.

Importance 80.0 Sentiment 50.0

per

Sawsan Abdel-Razig

Sawsan Abdel-Razig, Chief Academic Officer at Cleveland Clinic, highlighted the importance of academic partnerships in accelerating the development of safer therapies.

Importance 70.0 Sentiment 50.0

per

Mohamed Elsherif

Mohamed Elsherif, Research Associate at New York University and first author of the study, emphasized the technology's potential to bridge the gap between non-invasive therapies and traditional implants.

Importance 70.0 Sentiment 50.0

priv

Cleveland Clinic

Importance 0.0 Sentiment 0.0

ERGEN INTELLIGENCE

Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard